Masimo, which develops non-invasive patient monitoring products which measure oxygen level of blood and pulse rate, filed terms with the SEC Friday for its upcoming IPO. The firm plans to offer 11.9 million shares at a price range of $16 to $18 per share. Piper Jaffray, Deutsche Bank, and Citi are the lead managers on the deal.
